**Chief Medical Officer Directorate** 

Pharmacy and Medicines Division

αβχδ

26 August 2019

....

#### **Addresses**

For action
Chief Executives, NHS Boards
Directors of Pharmacy, NHS
Boards
Medical Directors, NHS Boards
General Practitioners
Community Pharmacists
Dispensing Doctor Practices

For information
Chief Executive, NHS NSS
Director of Practitioner
Services, NHS NSS

#### **Enquiries to:**

Jenny Hunt
Pharmacy & Medicines
Division
1st Floor East Rear
St Andrew's House
EDINBURGH
EH1 3DG

Tel: 0131-244-9719

Email:

jenny.hunt@gov.scot

www.gov.scot

#### Dear Colleague

# HORMONE REPLACEMENT THERAPY (HRT) SUPPLY ISSUES

## **Summary**

1. This Circular advises community pharmacy contractors and NHS Boards with the latest update on the availability of all Hormone Replacement Therapy (HRT) products marketed in the UK.

### **Background**

2. The Department of Health and Social Care (DHSC) are aware of the ongoing manufacturing issues that have affected the supply of some HRT products throughout 2019.

#### **Details**

- 3. The table 1 attached at Annex A provides the latest update on the availability of all HRT products marketed in the UK and the known resupply date for products that are currently experiencing supply issues.
- 4. The table also provides an update of all HRT preparations that remain available. Clinicians may be required to switch patients to alternative HRT products that contain the same active ingredients for a temporary period.
- 5. Prescribing information regarding HRT equivalence to support local decision making is available through various sources such as the British National Formulary, Summary of Product Characteristics (SPC), The Monthly Index of Medical Specialities (MIMS), and other sources including local Medicines Information Centres.

NHS Circular: PCA (P)(2019) 18

- 6. Clinicians are advised to work closely with community pharmacies to understand local availability of HRT products and use the table below to help make decision about appropriative HRT products for patients who are affected by the supply issues.
- 7. DHSC will continue to provide updates on HRT availability in the monthly supply report, which is uploaded to the Specialist Pharmacist Services website. All registered user can access this update via this following link (note that this is set up primarily for NHS England users): https://www.sps.nhs.uk/articles/department-of-health-and-pharmaceutical-market-strategy-group-pmsg
- 8. You are asked to note the content of this circular and bring to the attention of all relevant **community pharmacists**, **general practitioners**, **dispensing doctors and other healthcare professionals and teams**.

Yours sincerely

**Dr Rose Marie Parr** 

KoseMarie Park

Chief Pharmaceutical Officer and Deputy Director Pharmacy & Medicines Division

## **Table 1. HRT Availability**

		Oestrogen Only				
Ingredient (s)		Brand	Strength	Current Availability	Anticipated resupply	
	Manufacturer		Oral preparations		date	
Estradiol hemihydrate	Mylan	Elleste Solo* -	1mg	In stock	Continued availability to be confirmed. Please see below the table for more information on the Elleste range *	
			2mg	In stock		
	Mylan	Zumenon*	1mg	OOS	Mid-September 2019	
			2mg	OOS	End of August 2019	
Estradiol valerate	Bayer	Progynova -	1mg	In stock		
Esti autoi valei ate			2mg	In stock		
Estradiol	Resource Medical UK	Bedol	2mg	Long term OOS		
		Transde	rmal patches			
			25 mcg	In stock until mid to end of February 2020	Mid 2020 please see	
	Janssen-Cilag	Evorel **	50mcg	In stock until end of October 2019		
Estradiol			75mcg	In stock until be beginning of October mo	below the table for more information on the Evorel range**.	
			100mcg	In stock until beginning of October 2019		
	Novartis	Estradot	25 mcg	In stock		
			37.5mcg	In stock		
			50mcg	In stock		
			75mcg	In stock		
			100mcg	In stock		
		Estraderm -	25 mcg	In stock		
	Merus Labs/Norgine		50mcg	In stock		
Fakar dial bandhadaaka			75mcg	In stock		
Estradiol hemihydrate			100mcg	In stock		
	Theramex	FemSeven Mono	50mcg	In stock		
			75mcg	In stock		
			100mcg	In stock		
	Bayer	Progynova TS	50mcg	In stock		
			100mcg	In stock		
	Mylan	Elleste Solo MX *	40mcg	In stock	Continued availability	
			80mcg	In stock	to be confirmed	
Conjugated oestrogen	Pfizer	Premarin	300mcg	In stock		
			625mcg	In stock		
-			1.25mcg	In stock		
	Topical (T	ransdermal gels/	creams/other deliv			

NHS Circular: PCA (P)(2019) 18

PCA (P)(2019) 18	Besins	On atms = 1	0.000/	1			
Estradiol	Healthcare (UK) Ltd	Oestrogel	0.06%	In stock			
Estradiol hemihydrate	Orion	Sandrena	0.5mg	In stock			
	Orion	Sandrena	1mg	In stock			
	Pfizer	Estring vaginal delivery system	7.5mcg/ 24hours	In stock			
	Novo Nordisk	Vagifem vaginal tablets	10mcg	In stock			
	Flynn Pharma	Blissel	50mcg/g	In stock			
estriol	Marlborough Pharma	Estriol cream (generic)	0.01%	In stock			
	Aspen	Ovestin cream	1mg	In stock			
Progestogen only							
Medroxyprogesterone	Resource Medical UK	Climanor	5mg	long term OOS			
Levonorgestrel	Bayer	Mirena Intrauterine device	20mcg/24hrs	In stock			
	Besins Healthcare (UK) Ltd	Utrogestan	100mg	In stock			
Progesterone		Utrogestan	200mg	In stock			
	Combine	d HRTs (Pro	gestogen and	oestrogen)			
		Continuous o	combined therap	у			
		Oral p	reparations				
Estradiol hemihydrate /	Mylan	Elleste Duet Conti*	2mg / 1mg	In stock at wholesalers	Continued availability to be confirmed		
norethisterone acetate	Novo Nordisk	Kliofem	2mg/ 1mg	In stock			
	NOVO NOTUISK	Kliovance	1mg/ 500mcg	In stock			
Estradiol hemihydrate /	Mylan	Femoston	500mcg/ 2.5mg	In stock			
dydrogesterone		Conti	1mg/5mg	In stock			
Estradiol valerate/medroxyprogeste rone	Orion	Indivina	1mg /2.5mg	In stock			
			2mg/5mg	OOS	End of August 2019.		
			1mg/5mg	In stock			
low dose conjugated oestrogen/medroxyproges terone	Pfizer	Premique	300mcg/1.5mg	In stock			
		Transo	lermal patch				
Estradiol hemihydrate/ norethisterone acetate	Janssen-Cilag	Evorel Conti **	3.2mg/11.2mg	In stock - mid to end of October 2019	Mid 2020 See below **		
Estradiol hemihydrate/ levonorgestrel	Theramex	FemSeven C onti	1.5mg/ 0.525mg	Long term OOS	Q2 2020		
		Sequential c	ombined therapy	1			
Oral preparations							
Estradiol [X,X] / norethisterone acetate	Resource Medical UK	Clinorette	[2mg, 2mg]/ 1mg	Long term OOS			

## NHS Circular: PCA (P)(2019) 18

PCA (P)(2019) 18	)	Ī	i		•		
Estradiol/norgestrel		Cyclo- progynova	2mg/500mcg	Long term OOS			
Estradial hamibudgata /		Elleste Duet	1mg/ 1mg	In stock	Continued availability		
Estradiol hemihydrate / norethisterone acetate	Mylan	Mylan	*	2mg/ 1mg	In stock	to be confirmed	
Estradiol hemihydrate/		F	1mg/ 10mg	limited stock			
dydrogesterone		Femoston	2mg/10mg	In stock			
Estradiol hemihydrate / norethisterone acetate	Novo Nordisk	Novofem	1mg/ 1mg	In stock			
Estradiol valerate/ medroxyprogesterone acetate		Tridestra	2mg/20mg	In stock			
Estradiol hemihydrate [X,X,X]/ norethisterone acetate	Orion	Trisequens	[2mg, 2mg, 1mg]/ 1mg	In stock			
		Transo	lermal patch				
a) Estradiol hemihydrate and b) estradiol hemihydrate/ norethisterone acetate	Janssen-Cilag	Evorel Sequi**	a)3.2mg b) 3.2 mg /11.2 mg	In stock until mid- September 2019	Mid 2020 See below **		
a) 1.5mg of estradiol hemihydrate b) Estradiol hemihydrate /levonorgestrel	Theramex	FemSeven Se qui	a) 1.5mg b) 1.5mg /1.5mg	Long term OOS	Q2 2020		
Gonadomimetic (s)							
Tibolone 2.5mg	Advanz Pharma	Livial tablets	Tibolone 2.5mg	In stock			
Selective oestrogen receptor modulator							
Ospemifene 60mg tablets	Shionogi	Senshio tablets	Ospemifene 60mg tablets	In stock			
Tissue-selective oestrogen complex							
Conjugated oestrogen 300mcg/ bazedoxifene 20mg	Pfizer	Duavive	conjugated oestrogen 300mcg/ bazedoxifene 20mg	In stock			